Health Care

4487 posts

Bioxyne expands LATAM medicinal cannabis footprint with Costa Rica agreement

Bioxyne has signed an agreement for the first international supply of medicinal cannabis flower into Costa…

Amplia Therapeutics and ANZGOG to undertake ovarian cancer study

Amplia Therapeutics and the ANZOG have entered into an agreement to conduct a new clinical study…

Noxopharm brings in specialist support to help progress its US regulatory strategy

Clinical-stage Australian biotech company Noxopharm (ASX:NOX) has engaged a global clinical research organisation to support it in the lead-up to a pre-investigational
The Market Online Video

FDA greenlights Syntara’s Amsulostat Phase 2b, setting up big 2026 catalysts

Syntara has had a positive outcome from its in person Type C meeting with the US…
Detail of a representation of pain in the knee with red color on a bluish image. Side view.

Paradigm Biopharma advances Phase 3 OA Trial on tail of positive DSMB safety review

Paradigm Biopharma's pivotal Phase 3 PARA_OA_012 clinical trial will "proceed as designed" after a safety review…

Syntara receives positive feedback from FDA on amsulostat plans

Syntara has received positive feedback from the US FDA for the phase 2b study design for…

Biome Australia files first patent application for probiotic strain

Biome Australia has filed its inaugural patent application for proprietary next generation probiotic strain BMB18.

‘Meaningful reduction’: Avita achieves positive Cohealyx grafting study interim results

Avita Medical has unveiled a significant reduction in mean time to skin grafting in positive interim…
London

With osteo Phase 3 trial at 50% recruitment, Paradigm Bio inks partnership with University of London

Paradigm Biopharma (ASX:PAR) has this week hit two big items out the park: first of all, hitting 50% recruitment

Emyira ramps up national growth strategy with NSW recruitment campaign

Emyira has initiated a significant growth program with a targeted clinical workforce recruitment campaign underway in…